← All trials
NCT06051409
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Oct 31, 2028
- First posted
- Sep 22, 2023
- Last posted
- Sep 25, 2023
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Suzhou Medical CollegeOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Suzhou Medical CollegeOfficial
- Jiao Tong UniversityOfficial
- Ascentage Pharma Group Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.